8A-PDHQ explained

8a-Phenyldecahydroquinoline (8A-PDHQ) is a high affinity NMDA antagonist developed by a team at Parke Davis in the 1950s.^[1] It is a structural analog of phencyclidine with slightly lower binding affinity than the parent compound. (−)-8a-Phenyldecahydroquinoline has an in vivo potency comparable to that of (+)-MK-801.^{[2] [3]}

Notes and References

1. US Patent 3035059
2. Chen C, Kozikowski AP, Wood PL, Reynolds IJ, Ball RG, Pang YP . Synthesis and biological activity of 8a-phenyldecahydroquinolines as probes of PCP's binding conformation. A new PCP-like compound with increased in vivo potency . Journal of Medicinal Chemistry . 35 . 9 . 1634–8 . May 1992 . 1315871 . 10.1021/jm00087a020 .
3. Elhallaoui M, Laguerre M, Carpy A, Ouazzani FC . Molecular modeling of noncompetitive antagonists of the NMDA receptor: proposal of a pharmacophore and a description of the interaction mode . Journal of Molecular Modeling . 8 . 2 . 65–72 . February 2002 . 12032600 . 10.1007/s00894-001-0067-4 . 34882820 .